multiple sclerosis
Breakthrough multiple sclerosis research sheds light on cause of the disease
April 24, 2017Research and Development, Sales and Marketing multiple sclerosis
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be …
Celgene’s potential blockbuster gets positive Phase 3 results in multiple sclerosis
February 20, 2017Research and Development, Sales and Marketing Celgene, multiple sclerosis
Celgene’s drug to treat patients suffering with relapsing multiple sclerosis (RMS) was given a boost by positive Phase 3 trial …
Teva hit by patent blow upon top-selling MS drug
January 31, 2017Manufacturing and Production Mylan, Teva, generic, multiple sclerosis
Teva endured a rough ride in 2016, seeing its market value sink progressively over the course of the year. It …
Biogen shells out $1.25bn to protect best-selling MS drug
January 18, 2017Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera
Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …
Roche’s ground-breaking MS drug delayed by manufacturing issues
December 22, 2016Genentech, MS, Roche, multiple sclerosis
Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …
Apitope reclaims multiple sclerosis treatment from Merck after 7 years
October 17, 2016Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis
Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …
Roche’s Ocrevus more effective than Merck’s Rebif, company claims
September 14, 2016Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis
Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …
Positive Phase III results for Novartis MS drug
August 25, 2016Research and Development Novartis, multiple sclerosis, phase III
Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …
Teva loses patent protection on lucrative MS treatment
August 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis
Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis
July 7, 2016Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta
Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …
Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation
Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …
New high-risk treatment can halt MS, claim researchers
June 10, 2016Research and Development multiple sclerosis, research
The results of a Phase II clinical trial, published in The Lancet, suggests that a new use of chemotherapy followed …
Biogen MS drug misses primary endpoint in Phase II trial
June 8, 2016Research and Development Biogen, MS, multiple sclerosis, opicinumab
Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …
Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration
June 2, 2016Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III
Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
Biogen says European regulatory committee adopts positive view for Tysabri
June 1, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis
Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …
